Enhanced Compounds and Methods for Targeted Degradation of EZH2 Polypeptide

Improved compounds and methods for targeted degradation of EZH2 polypeptide, enhancing binding affinity, reducing off-target effects, and improving bioavailability, resulting in more efficient and safer treatment of diseases associated with EZH2 overexpression.

The original patent application Ser. No. 15/230,354 disclosed compounds and methods for the targeted degradation of EZH2 polypeptide. However, these compounds and methods have limitations, such as suboptimal binding affinity to the E3 ubiquitin ligase protein, off-target effects, and poor bioavailability. The new inventive concept addresses these limitations by introducing optimized E3 ubiquitin ligase binding moieties, modified compounds with reduced off-target effects, and formulations for improved bioavailability.

The new inventive concept comprises a system for targeted degradation of EZH2 polypeptide, including an E3 ubiquitin ligase binding moiety optimized for improved binding affinity to the E3 ubiquitin ligase protein, and a protein target binding moiety. The compounds are modified to reduce off-target effects and improve specificity for the EZH2 polypeptide. Additionally, the composition is formulated for improved bioavailability and reduced toxicity. The system also includes a sensor for detecting the levels of EZH2 polypeptide in a cell, integrated with a feedback loop to adjust the dosage of the compound. Furthermore, a method for identifying novel E3 ubiquitin ligase binding moieties is disclosed, comprising screening a library of compounds for binding affinity to the E3 ubiquitin ligase protein.

The new inventive concept introduces novel and non-obvious improvements over the original patent, including the optimized E3 ubiquitin ligase binding moieties, modified compounds with reduced off-target effects, and formulations for improved bioavailability. These improvements result in a more efficient and safer treatment of diseases associated with EZH2 overexpression.

Alternative embodiments of the inventive concept include varying the E3 ubiquitin ligase binding moiety, modifying the protein target binding moiety, or using different formulations for improved bioavailability. Additionally, the system could be adapted for use with different diseases associated with EZH2 overexpression, or for use in combination with other therapies.

The enhanced compounds and methods for targeted degradation of EZH2 polypeptide have significant commercial potential in the treatment of diseases associated with EZH2 overexpression, such as cancer and neurological disorders. The market for these treatments is expected to grow significantly in the coming years, driven by the increasing incidence of these diseases and the need for more effective and safer treatments.